Company intelligence / Profile preview

SoftWave Tissue Regeneration Technologies

Woodstock, Georgia, United Statessoftwavetrt.com ↗

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

SoftWave’s electrohydraulic shockwave devices are FDA-cleared for several indications including diabetic foot ulcers and second-degree burns. Clinical evidence supports efficacy in accelerating tissue regeneration and reducing inflammation and pain. Studies show success rates of 65–91% for musculoskeletal disorders. Recent research also demonstrates cardiac tissue regeneration post-coronary bypass surgery.

Therapeutic areas: DermatologyRheumatologyEndocrinologyInfectious Diseases
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Collaborates with leading research centers and professional sports organizations

Beyond the preview

Go deeper on SoftWave Tissue Regeneration Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SoftWave Tissue Regeneration Technologies.

Explore the full profile